Skip to main content
MedPathMedPath Home
Clinical Trials/NCT04455451
NCT04455451
Completed
Not Applicable

Intensive Care Therapy of Covid-19 Disease in Germany an Multi-center Observational Study

University Hospital Tuebingen27 sites in 1 country2,054 target enrollmentAugust 6, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCOVIDARDS

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID
Sponsor
University Hospital Tuebingen
Enrollment
2054
Locations
27
Primary Endpoint
Mortality
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Multi-center retrospective and prospective observational study of Covid-19 patients with severe or critical illness treated on a German ICU

Registry
clinicaltrials.gov
Start Date
August 6, 2020
End Date
September 30, 2021
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Age above 18 years
  • •Covid-19 disease (positive SARS-CoV-2 PCR)

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Mortality

Time Frame: up to 150 days

ICU Mortality of patients

Secondary Outcomes

  • ICU length of stay(up to 150 days)

Study Sites (27)

Loading locations...

Similar Trials

Completed
Not Applicable
Outcomes of Patients With COVID-19 in the Intensive Care UnitCoronavirus InfectionsCOVID-19Viral Pneumonia Human Coronavirus
NCT04336345Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran150
Recruiting
Not Applicable
Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.Chronic Lymphocytic LeukemiaIndolent B-Cell Non-Hodgkin LymphomaCOVID-19
NCT05803395Gruppo Italiano Malattie EMatologiche dell'Adulto954
Withdrawn
Not Applicable
FOLLOW-UP OF PATIENTS WITH COVID-19.Patient Admitted to Intensive Care Unit for COVID-19
NCT04609839University Hospital, Strasbourg, France200
Unknown
Not Applicable
Multiple-Center Retrospective Study of Severe and Critical COVID-19 in ShanghaiCOVID-19
NCT05422963Ruijin Hospital1,000
Completed
Not Applicable
Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab ApplicationCOVID-19Outcome, FatalTocilizumabInterleukin 6Critically Ill
NCT06233357University of Ulm95